| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184837 | Gynecologic Oncology | 2015 | 6 Pages |
Abstract
The bevacizumab, paclitaxel, and carboplatin regimen is active and tolerable in advanced and recurrent EMCA. Its impact awaits results of the recently completed randomized phase II trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Fiona Simpkins, Richard Drake, Pedro F. Escobar, Benjamin Nutter, Nabila Rasool, Peter G. Rose,